Nocopi Technologies Reports Third Quarter Results

NOCOPI TECHNOLOGIES INC/MD/ (NNUP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nocopi Technologies Reports Third Quarter Results KING OF PRUSSIA, PA – November 12, 2026 – Nocopi Technologies, Inc. (“Nocopi Technologies” or the “Company”; OTCQB: NNUP) today reported financial results for the quarter ended September 30, 2026. 2026 Third Quarter H

Event · Earnings
Original reporting
Published Nov 12, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NNUP
Bullish
high confidence
Mentioned
$NNUP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NNUPBullishMed
01

Why it matters

The earnings surprise and strong balance sheet are likely to attract speculative buying in the OTC market, though liquidity remains thin.

02

Market read

Primary earnings disclosure for a micro‑cap; may cause short‑term price movement but limited broader market impact.

03

What to watch

High reliance on a few license agreements and the lack of debt could mask cash‑flow volatility if renewals falter.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Nocopi Technologies filed a Form 8‑K reporting its third‑quarter 2026 financials, highlighting a dramatic revenue increase and a swing to profitability after acquiring Polymeric.

Company-level read

Ticker impact

$NNUPBullishHigh confidence
Context

Q3 2026 results show revenue up 763% to $3.329 M and net income of $1.397 M, a turnaround from a loss last year.

Expected impact

likely upward pressure as investors price in the surprise profit and cash balance

Evidence & confidence

The company posted unexpected profitability and a sizable cash pile, which are rare for a micro‑cap and can trigger buying interest.

Market effects

Shows growth potential in the niche digital‑ink licensing market, may lift peers with similar royalty models.

Limited to U.S. OTC market; minimal broader regional effect.

Low; micro‑cap earnings have little impact on global indices.

Counterpoint

The rapid revenue jump may be unsustainable; integration risks from the Polymeric acquisition could pressure margins.

Key entities

  • Nocopi Technologies Inc.

    OTC‑listed digital‑ink and licensing business that recently acquired Polymeric.

  • Polymeric

    Acquired firm whose operations are now integrated into Nocopi.

Related articles

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).

$PARKHighAI 8/10

Park Dental Partners Inc (PARK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 6%

Park Dental Partners Inc (PARK) reported Q3 2026 revenue of $64.9M, up 6% YoY, driven by acquisitions and clinical hours. The company acquired Village Family Dental for $39.1M, funded with cash, a small credit line draw, and stock. PARK updated its 2026 revenue outlook to $262M-$265M and adjusted EBITDA to $21.2M-$22.2M. Gross margin declined due to higher salaries and cybersecurity costs. The acquisition adds 47 doctors and expands PARK's footprint to North Carolina.